<?xml version="1.0" encoding="UTF-8"?>
<p>Our research also demonstrates that the recommended uses and recipients of publicly purchased antivirals during the H1N1 response differed from what LHDs had anticipated in their pre-pandemic plans, and that this resulted in additional difficulties. During the 2009 H1N1 pandemic, antivirals were generally available through normal wholesale and retail markets; as a result, the State health department recommended that LHDs use publicly purchased drugs for the treatment of uninsured or underinsured persons and for communities experiencing shortages [
 <xref ref-type="bibr" rid="B3">3</xref>,
 <xref ref-type="bibr" rid="B21">21</xref>]. For many health departments, this represented a significant shift in their pre-pandemic antiviral implementation strategy, which had focused on the use of publicly purchased antivirals for treatment of ill persons once retail supplies had been depleted and that had emphasized the role of antivirals in protecting healthcare workers and other first responders [
 <xref ref-type="bibr" rid="B4">4</xref>]. As a consequence, LHDs revised their plans to support these new strategies, though implementing and communicating these strategies caused a strain on some local health departments and community partners.
</p>
